StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$0.17−0.00 (-1.32%)

Close on Oct 19, 2026Market cap $16.84MP/E –Yield –

aTYR PHARMA free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

aTYR PHARMA's free cash flow for the twelve months ending Jun 30, 2026 was -$54.82M. For fiscal 2025 it was -$62.06M. The highest annual figure on record is -$15.50M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$62.06M–
FY2024Dec 31, 2024-$69.18M–
FY2023Dec 31, 2023-$37.44M–
FY2022Dec 31, 2022-$43.53M–
FY2021Dec 31, 2021-$33.27M–
FY2020Dec 31, 2020-$15.50M–
FY2019Dec 31, 2019-$20.09M–
FY2018Dec 31, 2018-$31.66M–
FY2017Dec 31, 2017-$43.68M–
FY2016Dec 31, 2016-$53.46M–
FY2015Dec 31, 2015-$37.46M–
FY2014Dec 31, 2014-$23.07M–
FY2013Dec 31, 2013-$17.96M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.42M–
Q1 FY2026Mar 31, 2026-$12.66M–
Q4 FY2025Dec 31, 2025-$12.23M–
Q3 FY2025Sep 30, 2025-$20.51M–
Q2 FY2025Jun 30, 2025-$13.90M–
Q1 FY2025Mar 31, 2025-$15.42M–
Q4 FY2024Dec 31, 2024-$13.16M–
Q3 FY2024Sep 30, 2024-$13.17M–
Q2 FY2024Jun 30, 2024-$20.46M–
Q1 FY2024Mar 31, 2024-$22.40M–
Q4 FY2023Dec 31, 2023-$11.08M–
Q3 FY2023Sep 30, 2023-$10.12M–
Q2 FY2023Jun 30, 2023-$14.41M–
Q1 FY2023Mar 31, 2023-$1.84M–
Q4 FY2022Dec 31, 2022-$11.49M–
Q3 FY2022Sep 30, 2022-$12.71M–
Q2 FY2022Jun 30, 2022-$9.17M–
Q1 FY2022Mar 31, 2022-$10.16M–
Q4 FY2021Dec 31, 2021-$8.10M–
Q3 FY2021Sep 30, 2021-$11.53M–
Q2 FY2021Jun 30, 2021-$7.79M–
Q1 FY2021Mar 31, 2021-$5.84M-408.9%
Q4 FY2020Dec 31, 2020-$5.41M–
Q3 FY2020Sep 30, 2020-$5.57M–
Q2 FY2020Jun 30, 2020-$6.42M–
Q1 FY2020Mar 31, 2020$1.89M–
Q4 FY2019Dec 31, 2019-$4.96M–
Q3 FY2019Sep 30, 2019-$4.28M–
Q2 FY2019Jun 30, 2019-$4.82M–
Q1 FY2019Mar 31, 2019-$6.03M–
Q4 FY2018Dec 31, 2018-$4.85M–
Q3 FY2018Sep 30, 2018-$6.50M–
Q2 FY2018Jun 30, 2018-$9.24M–
Q1 FY2018Mar 31, 2018-$11.08M–
Q4 FY2017Dec 31, 2017-$10.47M–
Q3 FY2017Sep 30, 2017-$9.34M–
Q2 FY2017Jun 30, 2017-$9.73M–
Q1 FY2017Mar 31, 2017-$14.15M–
Q4 FY2016Dec 31, 2016-$11.74M–
Q3 FY2016Sep 30, 2016-$14.75M–

More aTYR PHARMA figures

See a number that looks wrong?